What Is Co-Trimoxazole?

Compound Xinnuoming is a sulfa antibiotic, which is a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP). Enterobacteriaceae bacteria such as Greek bacteria, Klebsiella, Salmonella, Proteus, Morganella, Shigella, Neisseria, Neisseria meningitidis, and Haemophilus influenzae all have good antibacterial effects.

Fufang Xinnuoming

Compound Xinnuoming is a sulfa antibiotic, which is a compound of sulfamethoxazole (SMZ) and

This product is a compound preparation, each tablet contains the active ingredient sulfamethoxazole 0.4g and

The product is a white tablet.

Because many common clinical pathogenic bacteria often show resistance to this product, drug sensitivity results need to be referred to in the treatment of bacterial infections. The main indication of this product is the following infections caused by sensitive strains.

Escherichia coli, g

Prone to crystallized urine,

Common pediatric infants under 2 months are disabled. For the treatment of bacterial infections, infants over 2 months and weighing less than 40kg take SMZ 20 30mg / kg and TMP 4 6mg / kg once every 12 hours. The dosage for children weighing 40kg is the same as that used by adults.

treatment

Tablet: containing SMZ 0.4g, TMP 0.08g; injection: 2ml (containing SMZ 0.4g, TMP 0.08g).

Compound Xinnuoming (is composed of sulfamethoxazole and

The SMZ and TMP in this product are completely absorbed from the gastrointestinal tract after oral administration, and can absorb more than 90% of the dosage.

Also in vitro

Disable those who are allergic to SMZ and TMP;

Aggravated because the product prevents the metabolism of folic acid

Allergic reactions are more common and can manifest as

Since this product can compete with bilirubin in

The combined use of urinary alkalizing drugs can increase the solubility of the product in alkaline urine and increase excretion.

Cannot be combined with para-aminobenzoic acid. Para-aminobenzoic acid can be taken up by bacteria instead of the product. The two antagonize each other.

(3) When the following drugs are used together with this product, this product can replace the protein binding site of these drugs, or inhibit their metabolism, so that the drug action time is prolonged or a toxic reaction occurs. Therefore, when these drugs are used at the same time as this product, or they are used The dosage needs to be adjusted for subsequent use. Such drugs include oral anticoagulants, oral hypoglycemic agents, methotrexate, phenytoin, and thiopental.

Combination with myelosuppressive drugs may enhance the effect of such drugs on

The blood concentration of this product should not exceed 200 g / ml. If this concentration is exceeded, the incidence of adverse reactions will increase and the toxicity will increase.

Excessive short-term use of this product will cause loss of appetite, abdominal pain, nausea, vomiting, dizziness, headache, drowsiness, unconsciousness, mental depression, fever, hematuria, crystal urine, blood disease, jaundice, bone marrow suppression and so on. The general treatment is gastric lavage, vomiting, or a large amount of water after stopping the drug; infusion can be given when the urine volume is low and renal function is normal. During the treatment process, blood images and electrolytes should be monitored. If there are more obvious adverse reactions in the blood system or jaundice, they should be treated with hemodialysis. If bone marrow suppression occurs, first discontinue the drug and give 3 to 6 mg of folic acid intramuscularly once a day for 3 days or until the hematopoietic function returns to normal.

Long-term overdose of this product will cause bone marrow suppression, resulting in reduction of platelets, white blood cells and megaloblastic anemia. When symptoms of bone marrow suppression occur, patients should be injected intramuscularly with 5 to 15 mg of formyltetrahydrofolate daily until the hematopoietic function returns to normal.